Adverum Biotech
ADVM----
Adverum Biotech (ADVM)
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixober...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Adverum Biotech Analyst Rating
View MoreForecast & Rating
Nov 17, 2025Price forecast
--100.00%
Forecast & RatingBuy
6analysts
- Strong buy33.33%
- Buy0.00%
- Hold66.67%
- Sell0.00%
- Strong sell0.00%
News
- Unusual Whales · May 27 at 07:36 AM
Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight
- Tip Ranks · Mar 26 at 02:35 AM
Faron bolsters late-stage push with new CTO for lead cancer immunotherapy
- MorningStar · Mar 16 at 10:10 AM
AdvoCare Announces St. Patrick’s Day BOGO 50% Off Promotion on Daily Greens
- businessinsider · Dec 9, 2025 at 08:46 AM
Eli Lilly completes acquisition of Adverum Biotechnologies
- Market Beat · Dec 8, 2025 at 10:17 PM
Adverum Biotechnologies (NASDAQ:ADVM) CEO Buys $47,000.40 in Stock
- Market Beat · Dec 8, 2025 at 10:17 PM
Adverum Biotechnologies (NASDAQ:ADVM) COO Purchases $211,000.00 in Stock
